Reported about 11 hours ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech firm, has achieved a $12.5 million milestone from Rallybio linked to the advancement of REV102, an investigational treatment for hypophosphatasia. The company's stock experienced a nearly 7% increase following this development and other regulatory milestones. Recursion continues to enhance its AI-driven drug discovery capabilities through collaborations and innovations, positioning itself as a leader in biotech focused on rare diseases and oncology.
Source: YAHOO